Fishbein Fellow.
Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass (Drs Wilens, Faraone, and Biederman), Department of Epidemiology, Harvard School of Public Health, Boston, Mass (Dr Faraone).
Corresponding Author: Timothy E. Wilens, MD, Pediatric Psychopharmacology Unit (ACC 725), Massachusetts General Hospital, 15 Parkman St, Boston, MA 02114-3139 ([email protected]).
Funding/Support: This work was supported by grants R01 DA14419 (Dr Wilens) and R01MH57934 (Dr Faraone) from the National Institutes of Health.
Financial Disclosure: Dr Wilkens has received support from the National Institute on Drug Abuse, National Institute of Mental Health, McNeil Consumer and Specialty Pharmaceutical, Shire Laboratories Inc, CellTech, Eli Lilly & Co, GlaxoSmithKlineBeecham, and Novartis Pharmaceuticals. Dr Biederman receives research support from Shire Laboratories, Eli Lilly, Wyeth Ayerst, Pfizer Pharmaceutical, Cephalon Pharmaceutical, Novartis, Janssen Pharmaceutical, Stanley Medical Foundation, the National Institute of Mental Health; serves on the speaker's bureau for Eli Lilly, Pfizer, Novartis, Wyeth Ayerst, Shire, McNeil, and Cephalon; and is on the advisory boards of Eli Lilly, CellTech, Shire, Novartis, Janssen, Johnson & Johnson, Pfizer, and Cephalon. Dr Faraone receives research support from McNeil, Shire, Eli Lilly, the National Institute of Mental Health, the National Institute of Child Health and Development, and the National Institute of Neurological Diseases and Stroke; is a on the speaker's bureau for Eli Lilly, McNeil, and Shire; and has had an advisory or consulting relationship with McNeil, Noven Pharmaceuticals, Shire, and Eli Lilly.
